Neutralizing Antibodies to Nipah and Hendra Virus

Patent metadata

Field	Value
Publication number	US-2016272697-A2
Application number	US-201214114465-A
Country	US
Kind code	A2
Filing date	Apr 30, 2012
Priority date	Apr 28, 2011
Publication date	Sep 22, 2016
Grant date	—

Abstract

The invention described herein provides novel peptides. The novel peptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Nipah virus and/or Hendra virus.

First claim

What is claimed is:

1 . A peptide selected from the group consisting of:
a) a peptide comprising an amino acid sequence at least 78% identical to the amino acid sequence of SEQ ID NO: 2, b) a peptide comprising an amino acid sequence at least 82% identical to the amino acid sequence of SEQ ID NO: 2, c) a peptide comprising an amino acid sequence at least 86% identical to the amino acid sequence of SEQ ID NO: 2, d) a peptide comprising an amino acid sequence at least 91% identical to the amino acid sequence of SEQ ID NO: 2, e) a peptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 2, and f) a peptide comprising an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 2,
wherein the peptide does not comprise the amino acid sequence of SEQ ID NO: 1.

2 . The peptide of claim 1 , wherein the peptide comprises an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 3, the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5, the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, the amino acid sequence of SEQ ID NO: 8, the amino acid sequence of SEQ ID NO: 9, the amino acid sequence of SEQ ID NO: 10, the amino acid sequence of SEQ ID NO: 11, the amino acid sequence of SEQ ID NO: 12, the amino acid sequence of SEQ ID NO: 13, the amino acid sequence of SEQ ID NO: 14, the amino acid sequence of SEQ ID NO: 15, the amino acid sequence of SEQ ID NO: 16, the amino acid sequence of SEQ ID NO: 17, the amino acid sequence of SEQ ID NO: 18, the amino acid sequence of SEQ ID NO: 19, the amino acid sequence of SEQ ID NO: 20, the amino acid sequence of SEQ ID NO: 21, the amino acid sequence of SEQ ID NO: 22, and the amino acid sequence of SEQ ID NO: 23.

3 . An antibody or antibody fragment comprising the peptide of claim 1 , wherein the peptide is a heavy chain complementarity determining region (CDR).

4 . The antibody or antibody fragment of claim 3 , further comprising at least one additional heavy chain CDR.

5 . The antibody or antibody fragment of claim 4 , wherein the at least one additional heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 25.

6 . The antibody or antibody fragment of claim 5 , further comprising a second additional heavy chain CDRs.

7 . The antibody or antibody fragment of claim 6 , wherein the second additional heavy chain CDRs comprises the amino acid sequence of SEQ ID NO: 26.

8 . The antibody or antibody fragment of any of claims 3 - 7 , further comprising at least one light chain CDR.

9 . The antibody or antibody fragment of claim 8 , wherein the at least one light chain CDR comprises the amino acid sequence of SEQ ID NO: 27.

10 . The antibody or antibody fragment of claim 9 , further comprising a second light chain CDR.

11 . The antibody or antibody fragment of claim 10 , wherein the second light chain CDR comprises the amino acid sequence of SEQ ID NO: 28.

12 . The antibody or antibody fragment of claim 11 , further comprising a third light chain CDR.

13 . The antibody or antibody fragment of claim 12 , wherein the third light chain CDR comprises the amino acid sequence of SEQ ID NO: 29.

14 . A method of treating a Hendra virus or Nipah virus infection comprising administering the antibody or antibody fragment of claim 3 to a subject which has been infected with Hendra or Nipah virus.

15 . A method of reducing the likelihood of a subject developing a disease caused by Hendra virus or Nipah virus, the method comprising administering the antibody or antibody fragment claim 3 to a subject prior to Hendra virus infection or Nipah virus infection.

16 . A nucleic acid encoding the peptide of claim 1 .

17 . A vector comprising the nucleic acid of claim 16 .

18 . A host cell comprising the vector of claim 17 .

19 . A method of making a peptide comprising an amino acid of SEQ ID NO: 2, SEQ ID NO: 3; SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 23, the method comprising culturing the host cell of claim 18 under conditions suitable for protein expression and isolating the peptide.

20 . An antibody that binds to the four hydrophobic pockets of the G glycoprotein head of Hendra virus or Nipah virus.

Assignees

• Henry M Jackson Found Advancement Military Medicine Inc

Inventors

• Broder Christopher C
• Fusco Deborah L
• Xu Kai
• Nikolov Dimitar B

Classifications

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C07K16/11 Primary

  Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV] · CPC title